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Introduction: The prognostic value of oestrogen receptor (ER) and progesterone
receptor (PR) in early stage breast cancer remains uncertain. To evaluate the
prognostic role of the steroid receptors, a multivariate analysis should be used to
include the eﬀect of age and/or menopausal state and lymph node status on the
survival, since they are important discriminators of their prognostic value [3].
Besides the need for newer statistical methods, a longer follow-up period and a
homogeneous patient population seem important to detect non-proportional
eﬀects on hazards [3]. In 1998, Hilsenbeck stated that failure to recognise
violations of proportional hazards might lead to over- and under-estimation of
the eﬀects of important prognostic factors [2]. We wanted to check the time-
dependence of hazard ratios for steroid receptors in the Surveillance, Epidemi-
ology and End-Results (SEER) patient population.
Patients and methods: Women aged between 25 and 95 years at diagnosis with
histologically conﬁrmed non-metastatic T1–T2, node-negative or – positive
primary breast carcinoma, diagnosed between 1990 and 1997, who were treated
curatively and underwent axillary dissection, were abstracted from the SEER
Program [1]. ER- and PR-positivity were found in 43829 and 37907 patients,
respectively. Event was deﬁned as death from any cause. The follow-up cut-oﬀ
date was December 31, 1999. Cox proportional hazards models were used for
multivariate survival analysis. The time dependence of hazards was examined by
performing diagnostic plots of residuals with length of follow-up time. Variables
considered in the models were: tumour size, age and year at diagnosis, number of
nodes examined and number of nodes involved, registry area, race, marital
status, tumour topography, histological type and grade, steroid receptor status,
type of primary surgery, and administration of post-operative radiotherapy.
Subgroup analysis was performed by examining the interaction between ER and
PR with nodal status. Signiﬁcance level was set at P < 0.006 to adjust for the size
of the data and multiple comparisons.
Results: The multivariate analysis resulted in the following values for Hazard
Ratios for ER-positivity and PR-positivity for the overall patient population:
0.771 (0.732–0.811) and 0.890 (0.846–0.936), respectively. Subgroup analysis
revealed a Hazard Ratio for ER-positivity of 0.796 (0.742–0.854) for the node-
negative and 0.743 (0.689–0.800) for the node-positive subgroup. The Hazard
Ratio for PR-positivity was 0.975 (0.911–1.045) and 0.799 (0.742–0.860),
respectively. Thus, ER- and PR-positivity were both associated with a favourable
outcome, but PR-positivity was not signiﬁcant in the node-negative patients. A
check of hazards constancy over time showed that the favourable eﬀect of ER+
was constant only during the ﬁrst 3 years, after that it decreased progressively,
ER+ did not have a prognostic value after 6 years. The favourable eﬀect of PR+
remained almost constant up to the maximum observed follow-up period of 10
years. This test conﬁrmed a major departure from the proportional hazards
assumption for ER+ (P < 0.0001), and a minor departure for PR+ (P = 0.011).
Discussion: Our data suggest that PR appears to have a more constant
prognostic eﬀect over time than ER. This result conﬁrms the analysis done by
Costa and colleagues [3] that revealed that PR appeared to be superior to ER in
predicting the prognosis of primary breast cancer patients. However, subgroup
analysis suggests the presence of interaction eﬀects (PR was non-signiﬁcant in
node-negative patients). Further analysis of this data-set is warranted to
investigate the interactions and inﬂuence of age and systemic treatment. In
addition, more attention needs to be directed to the method and the cut-oﬀ level
of the steroid receptor assays.
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